Tyra Biosciences, Inc.
TYRA
$31.88
$0.943.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.85% | 10.13% | 26.54% | 29.05% | 34.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.86% | 22.77% | 15.17% | 33.66% | 42.68% |
| Operating Income | -31.86% | -22.77% | -15.17% | -33.66% | -42.68% |
| Income Before Tax | -39.64% | -32.31% | -24.37% | -50.24% | -54.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.64% | -32.31% | -24.37% | -50.24% | -54.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.64% | -32.31% | -24.37% | -50.24% | -54.72% |
| EBIT | -31.86% | -22.77% | -15.17% | -33.66% | -42.68% |
| EBITDA | -32.02% | -22.92% | -15.23% | -33.78% | -42.82% |
| EPS Basic | -34.19% | -30.60% | -22.70% | -47.99% | -36.20% |
| Normalized Basic EPS | -34.17% | -30.60% | -22.71% | -48.04% | -36.20% |
| EPS Diluted | -34.19% | -30.60% | -22.70% | -47.99% | -36.20% |
| Normalized Diluted EPS | -34.17% | -30.60% | -22.71% | -48.04% | -36.20% |
| Average Basic Shares Outstanding | 4.06% | 1.31% | 1.35% | 1.50% | 13.61% |
| Average Diluted Shares Outstanding | 4.06% | 1.31% | 1.35% | 1.50% | 13.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |